Core Insights - IDEXX Laboratories, Inc. (IDXX) has updated its 2025 EPS outlook to a range of $12.81 - $13.01, reflecting a $0.33 increase at midpoint due to operational performance and tax rate benefits [1] - The company has revised its full year revenue growth guidance to $4.27 billion - $4.30 billion, indicating a reported growth of 9.6% - 10.3% [2] - For Q3, IDEXX reported earnings of $274.61 million, or $3.40 per share, a significant increase from $232.84 million, or $2.80 per share, in the previous year [3] Financial Performance - The updated EPS growth outlook is projected at 20% - 22% as reported and 12% - 14% on a comparable basis [1] - The company increased its outlook for organic revenue growth to 8.8% - 9.5%, marking an approximate 1% increase at midpoint [2] - Revenue for Q3 rose by 13.3% to $1.105 billion from $975.54 million year-over-year [3] Market Reaction - Shares of IDEXX are up 5% in pre-market trading following the earnings announcement [4]
IDEXX Raises 2025 EPS Guidance